Effect of xantina oxidasi inhibition on left ventricular function and on energetic stores of the haert in patients affected by chronic cardiac insufficiency. - ND

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2009-015958-38-IT

Enrollment

Registered

2009-09-15

Start date

2009-09-30

Completion date

Unknown

Last updated

2021-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients affected by cardiac insufficiency MedDRA version: 9.1 Level: PT Classification code 10007554

Interventions

Trade Name: ZYLORIC Pharmaceutical Form: Tablet INN or Proposed INN: Allopurinol Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300-

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients aged between 50 and 90 years old; FE or equal to 8 mg/die; cardiac insufficiency from about 6 months; steady basal therapy for at least 2 months; NYHA II-III class Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: diseases that may interfere with the study; enrollment in other clinical study;climateric women in hormonal therapy; instable angina or malignant heart block;untreated ipokaliemia; intollerance to allopurinolo; intake of drugs that may induce iperuricemia; patients unable to take part to the study and to underwent the tests

Design outcomes

Primary

Measure	Time frame
Main Objective: to evaluete the netabolic effect of allopurinolo in patients with cardiac insufficiency and incremented uric acid values;Secondary Objective: to evaluete the netabolic effect of allopurinolo in patients with cardiac insufficiency and incremented uric acid values;Primary end point(s): evaluation of the changes of PCr/ATP values after addition of allopurinole to conventional therapy for cardiac insufficiency.	—

Measure

Time frame

Main Objective: to evaluete the netabolic effect of allopurinolo in patients with cardiac insufficiency and incremented uric acid values;Secondary Objective: to evaluete the netabolic effect of allopurinolo in patients with cardiac insufficiency and incremented uric acid values;Primary end point(s): evaluation of the changes of PCr/ATP values after addition of allopurinole to conventional therapy for cardiac insufficiency.

—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026